Levocom

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levocom

Property Description
Active ingredient Levofloxacin
Pharmacological class Fluoroquinolone Antibacterial Agent
Forms Tablets (oral), Solution for Infusion (IV)
General purpose Resolves systemic bacterial infections
Origin Synthetic

Levocom is a synthetic, prescription-only medicine containing the active ingredient Levofloxacin, which is a high-potency antibacterial agent of the fluoroquinolone class. Levofloxacin is chemically recognized as the purified L-isomer of Ofloxacin—the active component—establishing it as a third-generation fluoroquinolone. This specific structure is clinically recognized for conferring enhanced efficacy against a wider range of susceptible organisms compared to earlier quinolones.

As a single-component product, Levocom delivers its therapeutic effect solely through Levofloxacin. The substance is entirely synthetic in origin and is designed for systemic administration throughout the body. It is supplied as film-coated tablets for oral use and as a sterile solution for infusion for intravenous (IV) delivery. The high absorbability of Levofloxacin allows for a practical switch from IV administration to tablets, a beneficial feature that maintains consistent infection control during extended treatment periods.

The primary purpose of this medicine is the effective clearance of established systemic bacterial infections. Its mechanism is defined by a bactericidal action, actively killing the susceptible bacteria rather than merely halting their growth. The fundamental scientific principle involves the specific inhibition of two bacterial enzymes, DNA gyrase and Topoisomerase IV. This targeted disruption of the bacteria's ability to process and replicate their DNA is the basis for its powerful, definitive effect in resolving the infectious cause of illness.

Regulatory References

  1. Levofloxacin Drug Record (NIH/DailyMed)

What side effects are possible with Levocom?

The safety profile of Levocom, containing the fluoroquinolone Levofloxacin, is formally structured by government regulatory agencies based on observed adverse reactions. Reactions are classified by frequency and the affected System-Organ Class (SOC).

Adverse Reaction Categories

Frequency Category Representative Adverse Reactions
Common Nausea, Diarrhea, Headache, Insomnia, Constipation, Dizziness.
Uncommon Vomiting, Abdominal pain, Fungal infection, Anxiety, Tremor.
Rare Tendinitis, Convulsions, Psychotic reactions, Hypoglycemia, Pseudomembranous colitis.

The official label lists serious adverse reactions with the potential to be disabling and potentially irreversible. These include Tendinitis and Tendon Rupture, Peripheral Neuropathy (nerve damage), and Central Nervous System effects (e.g., anxiety, confusion, seizures). Other documented serious risks are Prolongation of the QT Interval (a specific heart rhythm change), Aortic Aneurysm and Dissection, and Clostridium difficile-associated disease.

Safety Considerations

Regulatory documents include specific safety constraints for certain populations and conditions. Older adults and patients with renal impairment have a higher documented risk of specific adverse effects, including tendon disorders. Use in pediatric patients is generally restricted due to the potential for joint damage, as noted in regulatory findings.

Time-related safety patterns indicate that serious effects such as tendon rupture may occur during or up to several months after treatment completion, while certain CNS and allergic reactions may occur after the first dose. Official constraints also dictate that the medicine is contraindicated in patients with a history of myasthenia gravis, epilepsy, or prior fluoroquinolone-associated tendon disorders.

Overdose and Emergency Response

Officially Documented Overdose Manifestations

Official regulatory documents define the acute overdose profile of Levocom (Levofloxacin) by listing expected severe clinical manifestations, primarily involving the Central Nervous System (CNS) and the cardiovascular system. The most important neurological signs expected following excessive exposure are confusion, dizziness, and impairment of consciousness. The official prescribing information also documents the risk of convulsive seizures as a severe neurological outcome.

Furthermore, high systemic concentrations create a specific risk of Prolongation of the QT interval in the cardiovascular system, which is a life-threatening event mandating specialized monitoring in the overdose setting.

Emergency Actions and Required Care

Regulatory authorities mandate that you seek emergency medical attention or contact a Poison Control Center immediately upon suspected overdosage. Management is strictly defined as symptomatic and supportive treatment and requires the patient to be carefully observed in a clinical setting. Due to the identified cardiotoxicity risk, continuous ECG monitoring should be undertaken. Official labeling states that no specific antidote exists for Levofloxacin. For patients with renal considerations, regulatory documents specify that clearance procedures such as haemodialysis or peritoneal dialysis are not effective for removing the drug from the body.

Therapeutic Uses of Levocom

Levocom (Levofloxacin) is a broad-spectrum antibacterial agent generally used to address bacterial infections across major body systems. The core therapeutic benefit provided is supporting the resolution of the infectious cause, which may assist with easing symptomatic discomfort and contributing to patient comfort.

Levocom is commonly used to manage conditions characterized by periods of heightened symptoms in the lungs, urinary tract, prostate, and skin. This includes infections such as pneumonia, acute bacterial exacerbation of chronic bronchitis, acute pyelonephritis, complicated urinary tract infections, chronic bacterial prostatitis, and serious skin and soft tissue conditions like cellulitis.

“The primary purpose is to address the bacterial pathogen, which helps manage symptoms that interfere with daily functioning and supports general well-being during symptomatic phases.”

Symptom Management Domains

Levocom is applied in clinical settings that involve acute or unstable symptom patterns, where short-term symptomatic assistance is needed. It supports symptom management in conditions where symptoms related to physical discomfort (like pain, fever, or difficulty breathing) or systemic imbalance are present. This generally assists with maintaining functional stability and contributes to easing the overall symptom load during difficult episodes.


Quick Fact: Addressing Dysuria Quick Fact: Managing Systemic Imbalance
Dysuria (painful urination): In urinary infections, the medicine supports the management of this and other irritative symptoms like frequency. Systemic Imbalance: The medication assists in managing fever and other symptoms related to systemic imbalance that arise from acute illness.

Eligibility and Restrictions for Use

Who Can and Cannot Use Levocom?

The eligibility for using Levocom (Levofloxacin) is strictly defined by regulatory documents, focusing on absolute exclusions and specific risk factors associated with the fluoroquinolone class. Use is generally reserved for patients who have no alternative treatment options for certain milder infections, such as uncomplicated urinary tract infections.

Absolute Exclusions and Contraindications

Population/Condition Regulatory Status
Hypersensitivity to Levofloxacin or other quinolones Contraindicated
History of tendon disorders related to fluoroquinolone use Contraindicated
Children and growing adolescents (generally under 18) Contraindicated (except for specific life-threatening uses like anthrax)
Known history of Myasthenia Gravis Avoidance Required
Patients with epilepsy Contraindicated

Conditional Use and Restrictions

Use is permitted only with explicit caution and oversight for patients who are older adults (due to increased risk of tendon and cardiovascular issues) or those with renal impairment, which requires a mandatory dose adjustment. Levocom is generally not recommended or contraindicated for women who are pregnant or breastfeeding.

This eligibility structure defines who is allowed to use the medicine by establishing clear prohibitions based on historical drug reaction, age-related risk, and specific pre-existing comorbidities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Levocom (levofloxacin) interacts with several medication classes and substances, primarily affecting its absorption, increasing exposure of other drugs, or causing additive side effects.

Clinically Significant Pharmacokinetic Interactions

Interacting Product Category Effect on Levocom/Co-administered Drug
Multivalent Cation Products (Antacids, Iron, Zinc, Sucralfate) Significantly decreased absorption of Levocom.
Probenecid or Cimetidine Increased systemic exposure of Levocom (due to reduced renal clearance).
Ciclosporin Increased exposure of Ciclosporin (via inhibition of its metabolism).

Pharmacodynamic Interactions and Combination Risks

Co-administration with the following drug categories requires caution or avoidance due to documented additive risks:

  • Drugs known to prolong the QT interval (e.g., Class IA and III antiarrhythmics, tricyclic antidepressants) may lead to an increased risk of serious cardiac rhythm disturbances.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as fenbufen, may increase the risk of central nervous system (CNS) stimulation, including convulsions.
  • Corticosteroids increase the risk of tendon inflammation and rupture, a risk which is heightened in elderly patients.
  • Vitamin K Antagonists (e.g., Warfarin) can have their anticoagulant effect augmented, requiring mandatory monitoring of INR/Prothrombin Time.

Administration Requirements

Oral Levocom must be taken at least two hours before or two hours after products containing magnesium, aluminum, iron, calcium, or zinc to prevent chelation and subsequent loss of effect.

Mechanism of Action

How Levocom Works: Mechanism of Action

Levofloxacin is a bactericidal agent whose mechanism centers on the inhibition of two essential bacterial enzymes: DNA Gyrase and Topoisomerase IV. The drug binds to and stabilizes the cleavable complex formed by these enzymes and the bacterial DNA, preventing the crucial process of DNA strand re-ligation.

This molecular interference halts the bacteria's ability to supercoil its DNA (Gyrase) and to separate its daughter chromosomes during cell division (Topoisomerase IV), leading to the disruption of microbial function. By preventing re-ligation, Levofloxacin initiates a cascade where the enzymes are converted into cellular poisons, causing the catastrophic accumulation of double-strand DNA breaks (DSBs) throughout the bacterial genome. This lethal damage immediately arrests all essential bacterial life processes, leading to direct bactericidal action.

The efficacy of this mechanism is constrained by bacterial defense systems, including mutations in the target genes (GyrA/ParC) that reduce binding affinity, and the activity of efflux pumps which actively expel the drug from the cell. In the presence of these resistance factors, the drug cannot achieve the concentration needed at the target site to induce the lethal damage cascade.

Dosage and Administration Information

Levocom (Levofloxacin) is administered either orally via film-coated tablets or intravenously (IV) through a solution for slow infusion. Treatment often begins with the IV route and may transition to the oral tablet form at the same dosage upon clinical improvement, a practice supported by high oral bioavailability. The dosage is typically standardized to 250 mg, 500 mg, or 750 mg and administered once every 24 hours.

Duration of use is specific to the condition, ranging from a short course of approximately three days to extended periods of up to four weeks. Oral administration permits intake with or without food. However, tablets must be taken at least two hours before or two hours after ingesting mineral supplements or antacids containing magnesium, aluminum, iron, or zinc to avoid absorption interference.

A critical procedural constraint is the mandatory dose adjustment for adults with impaired kidney function, specifically when the Creatinine Clearance (CrCl) is leq 50 mL/min. The intravenous solution requires strict adherence to slow infusion rates; for example, 500 mg must be administered over a minimum of 60 minutes, with rapid IV injection being strictly prohibited. Pediatric use is generally restricted and subject to specific age and weight-based criteria.

Recent Clinical Evidence

Research evidence / Overview of studies for Levocom (Levofloxacin)


Evidence for use in Systemic Respiratory Infections

Levocom (Levofloxacin) was studied for its use in respiratory infections, primarily Community-Acquired Pneumonia (CAP). The primary research conducted involved numerous randomized controlled trials (RCTs) designed to evaluate Levofloxacin or different ways of administering the medicine itself.

The main focus of these trials was on two primary outcomes related to systemic or functional imbalance: the Clinical Success Rate and the Microbiologic Eradication Rate. Studies primarily monitored adult patients with CAP. Findings describe patterns observed in the studies where measurements for clinical outcomes and bacterial eradication were reported alongside the findings from comparator groups.

Evidence for use in Complicated Urinary Tract and Kidney Infections

Levocom was evaluated in research exploring its use for Complicated Urinary Tract Infections (cUTI) and a specific type of acute kidney infection. This research often involved randomized controlled trials to explore short-term symptom changes, with some trials including other antibiotics or different duration schedules for evaluation. Research describes specific measurements related to symptom resolution and microbiologic status being reported at the end of the therapy period.

Regulatory Context for Non-Severe Infections

Research has also explored the use of Levocom for conditions involving periods of heightened symptoms such as Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB). However, for non-severe infections, regulatory bodies, such as the U.S. Food and Drug Administration (FDA), have issued mandates that apply to the entire class of antibiotics (fluoroquinolones), reserving their use for patients with no alternative treatment options. Regulatory action resulted in the use of the medicine being reserved for specific situations, based on documented class-wide evidence.

What is Still Uncertain about Levocom Research

Certain aspects of the evidence base remain uncertain. The primary area of research limitation surrounds the ongoing monitoring of antimicrobial resistance. Furthermore, the available evidence provides limited information for long-term outcomes that extend beyond the typical post-treatment follow-up window. While research provides insight into short-term changes, information related to the durability of the observed status over many months remains limited. Research provides context but not individual predictions.

Key Studies & References Levofloxacin for community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials

Frequently Asked Questions (FAQ)

Common questions about Levocom (FAQ)

Q: How quickly should I expect to feel better after starting Levocom?

A: The time it takes to feel better can vary widely depending on the type and severity of the infection. Official clinical trials measure success at specific follow-up points after treatment. While studies show that the drug reaches therapeutic levels quickly, patients are generally directed to continue the course as prescribed, even if symptom improvement is noticed soon after starting.

Q: Why is it important to take the full course of Levocom even if I feel better?

A: Completing the full prescribed course is emphasized in official guidance. Stopping an antibiotic prematurely, even when symptoms resolve, can decrease the treatment’s effectiveness. This action also increases the likelihood that the bacteria causing the infection may develop resistance to the medication.

Q: Does Levocom have a risk of tendon-related side effects?

A: Official regulatory documents include a boxed warning about the risk of tendinitis and tendon rupture. This is a serious adverse reaction associated with Levocom (Levofloxacin) and other drugs in its class. This effect can potentially occur while an individual is taking the medicine or sometimes up to several months after treatment is complete.

Q: Can people with a history of kidney problems take Levocom?

A: Patients with known kidney problems require careful consideration and monitoring. Official product information states that a mandatory adjustment of the dose must be made if kidney function is reduced. The dose is typically adjusted by the prescribing professional based on the individual's kidney function test results.

Q: What's the typical duration of treatment with Levocom?

A: The length of treatment is specific to the infection being treated, as defined by official guidelines. Treatment can range from a short course of a few days (e.g., three days for certain simple infections) to more extended periods, with some approved uses lasting up to four weeks or more.

Q: Why do some doctors prescribe Levocom over other similar drugs?

A: Levocom is a third-generation fluoroquinolone and is recognized for its efficacy against a broad range of susceptible organisms. The prescribing professional's choice to use this medicine is typically based on the specific type of bacterial infection, local resistance patterns, and the drug’s ability to target the specific organism.

Q: Are there any long-term effects associated with Levocom use?

A: Official warnings highlight serious adverse reactions that have the potential to be disabling and may be potentially irreversible. These include effects like peripheral neuropathy (nerve damage) and tendon rupture, which can manifest during treatment or for a period of months afterward.

Q: What happens if a dose of Levocom is accidentally missed?

A: Official patient instructions typically advise that a missed dose should be taken as soon as it is remembered, unless it is nearly time for the next dose, in which case the missed dose is skipped. Doubling the dose to compensate is generally not recommended.

Q: Can Levocom be crushed or chewed if someone has trouble swallowing pills?

A: Levocom is supplied as a film-coated tablet. Regulatory information does not advise crushing or chewing the tablets. Film-coated tablets are typically meant to be swallowed whole to ensure the medicine is delivered correctly and to maintain the stability of the dosage.

Q: What is the success rate of Levocom for its approved uses?

A: Clinical success and bacterial eradication rates are reported in the clinical studies section of regulatory documents. These rates are findings from clinical trials and vary depending on the specific condition being treated, such as community-acquired pneumonia or urinary tract infections.

Q: What is the maximum recommended period of use for Levocom?

A: Regulatory information specifies that the duration of treatment is infection-specific. For its primary uses, courses typically run for up to four weeks, but extremely limited approved uses (like post-exposure anthrax prophylaxis) can extend up to 60 days.

Q: Can Levocom cause problems with sleep or insomnia?

A: Official product information lists insomnia, which is difficulty sleeping or an inability to sleep, as a common adverse reaction. If sleep disturbances occur while taking this medicine, it is recommended to discuss this with a healthcare professional.

Q: Are there any specific foods or drinks to avoid while on Levocom?

A: There are no general food restrictions, and the tablets can be taken with or without food. However, products containing high levels of multivalent cations, such as antacids or iron supplements, must be taken at least two hours before or two hours after Levocom to prevent the drug from being poorly absorbed.

Q: Is Levocom known to interact with caffeine?

A: Official information indicates that Levofloxacin may increase the effects of other similar drugs (methylxanthines). For this reason, patients are sometimes advised to limit or avoid the consumption of caffeine-containing products as it may increase potential side effects.

Q: Can Levocom affect blood sugar levels, especially for non-diabetics?

A: Official warnings highlight that Levocom can cause blood sugar disturbances, including both significantly low blood sugar (hypoglycemia) and high blood sugar (hyperglycemia). These effects can potentially occur in patients with or without a history of diabetes.

Q: Is it normal to feel a little dizzy or lightheaded when starting Levocom?

A: Dizziness is listed in official documents as a common adverse reaction associated with this medication. Patients should be aware of this possibility, particularly when starting treatment. This should be monitored and discussed with a healthcare professional if persistent or severe.

Q: Does Levocom cause changes in mood or anxiety?

A: Yes, Levocom can cause central nervous system effects. Official adverse reaction reports include anxiety, confusion, and insomnia. Rare cases of psychotic reactions have also been reported.

Q: What should I do if I experience unexpected diarrhea while on Levocom?

A: Diarrhea is a common side effect of many antibiotics. However, if diarrhea is persistent, severe, or contains blood, official warnings advise seeking guidance from a healthcare professional immediately. This may indicate a sign of a more serious condition like Clostridium difficile-associated disease.

Q: Is Levocom considered a first-line treatment for its primary uses?

A: For certain milder infections, such as uncomplicated urinary tract infections, regulatory bodies have issued mandates. These recommend reserving Levocom and other drugs in its class for patients who have no alternative treatment options, due to the potential for serious side effects.

Q: Are there any known interactions between Levocom and alcohol?

A: While there is no formal pharmacokinetic interaction listed with alcohol, central nervous system side effects such as dizziness and confusion are associated with Levocom. Patients are generally advised to limit or avoid alcohol due to the potential for it to worsen these effects.

Q: Is it safe to drive or operate machinery while taking Levocom?

A: Official regulatory information advises caution regarding activities that require mental alertness. It is advised that activities requiring mental alertness, such as driving or operating machinery, should be avoided until an individual knows how the medication affects their concentration and reaction time.

Q: Why do people sometimes get 'thrush' or yeast infections after taking Levocom?

A: Antibiotics, including Levocom, work by killing susceptible bacteria. This process can unintentionally alter the normal balance of microorganisms in the body. This imbalance can sometimes allow non-susceptible organisms, like yeast, to overgrow, leading to a fungal infection.

Q: Does Levocom cause increased sensitivity to the sun?

A: Yes, phototoxicity (increased sensitivity to the sun) is a known adverse reaction. Official warnings recommend avoiding unnecessary or prolonged exposure to sunlight and tanning beds. If sun exposure is unavoidable, official guidance typically recommends protective measures, such as wearing loose-fitting clothing and using sun protection.

Q: Does Levocom have a warning about potential nerve damage?

A: Official regulatory boxed warnings highlight the risk of peripheral neuropathy, which is a type of nerve damage. Symptoms may include pain, burning, tingling, or numbness, typically in the arms or legs. This adverse effect may be potentially irreversible.

Q: Can Levocom cause stomach upset or nausea?

A: Yes, nausea is a very common adverse reaction listed in official product information. Other common gastrointestinal effects include diarrhea and, less frequently, vomiting or abdominal pain.

Q: Does Levocom lose effectiveness if not taken at the same time every day?

A: Levocom is prescribed to be taken once every 24 hours. Taking the medicine at the same time each day is important for maintaining consistent drug levels in the blood, which helps to ensure the medication works effectively to fight the infection.

Q: Has Levocom been studied extensively in younger populations?

A: Use in children and growing adolescents is generally restricted or contraindicated in official documents. This is due to the potential for irreversible joint and cartilage damage. Approved uses for pediatric patients are limited to specific, severe conditions where the clinical benefit is judged to outweigh the known risks.

Q: How long does Levocom stay in your system after the last dose?

A: Regulatory pharmacokinetic data indicates that the medicine has a half-life of approximately 6 to 8 hours. The medicine is primarily eliminated through the kidneys, and it takes several half-lives for the drug to be almost completely cleared from the body.

Q: Can Levocom affect heart rhythm in some individuals?

A: Official warnings mention the potential for Levocom to cause a rare but serious heart rhythm problem called QT interval prolongation. The risk of this abnormal heart rhythm is increased in patients with certain pre-existing heart conditions or uncorrected electrolyte imbalances.

Q: What are the signs of a non-serious versus a serious side effect from Levocom?

A: Non-serious common effects typically include mild nausea, headache, or dizziness. Serious side effects that require immediate medical attention include signs of a severe allergic reaction (like swelling or difficulty breathing), tendon pain, or symptoms of nerve damage (like tingling or numbness in the limbs), according to official patient safety guides.

Q: Is there a risk of developing antibiotic resistance with Levocom?

A: Yes, like all antibacterial agents, official product information notes the risk of developing drug-resistant bacteria. To minimize this risk, Levocom should only be used to treat bacterial infections that are known or strongly suspected to be caused by susceptible bacteria.

Q: Are there published guidelines for the appropriate use of Levocom?

A: Official regulatory agencies have issued specific mandates and warnings that define the appropriate use of Levocom. These guidelines restrict its use for certain non-severe infections, stating that it should be reserved for patients who have no alternative treatment options.

How should Levocom be stored and disposed of?

How to Store and Dispose of Levocom (Levofloxacin)

Levocom must be stored and handled according to specific regulatory requirements to maintain its stability and effectiveness.


Storage Conditions

Requirement Official Regulatory Rule
Temperature Store at 20^circC to 25^circC (68^circF to 77^circF); excursions up to 30^circC are permitted.
Protection Keep the medicine protected from light and store in its original container with the bottle tightly closed.
Security The product must be stored out of the sight and reach of children.
Handling Note The Levofloxacin intravenous solution must not be frozen.

Disposal Instructions

Unused or expired Levocom must be disposed of according to local regulatory requirements. The medicine must not be flushed down the toilet or poured into a drain. Disposal should preferably be managed through an official drug take-back program to ensure proper pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levocom found in:

A-Z Index: